Ozempic is a once-weekly injectable medication containing semaglutide, a drug that mimics a natural gut hormone to reduce appetite and slow digestion. It is FDA-approved for type 2 diabetes, not for weight loss. However, doctors widely prescribe it off-label for weight management because it produces significant fat loss, and its active ingredient is the same one found in Wegovy, which is FDA-approved specifically for obesity.
How Ozempic Causes Weight Loss
Your gut naturally produces a hormone called GLP-1 after you eat. Semaglutide is a synthetic version of that hormone, engineered to last much longer in your body. It works through two main pathways.
First, it activates receptors in the brain’s hunger-control centers, dialing down appetite at a neurological level. People on semaglutide consistently report that food simply occupies less mental space. Cravings weaken, portions shrink naturally, and the constant background noise of hunger quiets down.
Second, it slows the rate at which your stomach empties into the small intestine. Food sits in your stomach longer, which extends the feeling of fullness after a meal. The combined effect of reduced hunger signals and prolonged satiety leads to a meaningful drop in daily calorie intake without the white-knuckle willpower that traditional dieting demands.
How Much Weight People Actually Lose
The landmark STEP 1 trial tested semaglutide at 2.4 mg per week (the Wegovy dose, higher than the typical Ozempic dose) in over 1,900 adults with obesity. After 68 weeks, participants lost an average of 14.9% of their body weight, compared to 2.4% in the placebo group. For someone starting at 220 pounds, that translates to roughly 33 pounds.
Most people notice initial changes around weeks four to five, but meaningful weight loss typically kicks in between months three and six, once the dose has been increased to its full therapeutic level. Experts recommend giving the medication at least eight weeks before judging whether it’s working.
Results vary. Some people lose considerably more than the average, others less. Diet and exercise amplify the effect, and clinical trials required participants to follow a reduced-calorie diet alongside the medication.
Ozempic vs. Wegovy: The Key Distinction
Ozempic and Wegovy contain the exact same drug, semaglutide. The difference is regulatory. Ozempic is approved for type 2 diabetes and tops out at a 2 mg weekly dose. Wegovy is approved for weight management in adults and adolescents with obesity (BMI of 30 or higher), or with a BMI of 27 or higher plus at least one weight-related health condition. Wegovy’s maximum dose is 2.4 mg.
When your doctor prescribes Ozempic specifically for weight loss, that’s considered off-label use. It’s legal and common, but it can affect insurance coverage. Many insurers will cover Wegovy for weight loss but not Ozempic for the same purpose, or vice versa, depending on the plan.
How the Dosing Schedule Works
Ozempic starts at 0.25 mg once a week for the first four weeks. This low introductory dose isn’t expected to produce much weight loss. Its purpose is to let your body adjust and minimize side effects. At week five, the dose increases to 0.5 mg. From there, your doctor may increase it further based on your response, up to a maximum of 2 mg per week.
You inject it yourself using a prefilled pen, typically in the abdomen, thigh, or upper arm. The injection is subcutaneous (just under the skin) and uses a thin needle that most people describe as painless or close to it. You pick one day of the week and stick with it.
Common Side Effects
Gastrointestinal issues are by far the most frequent complaint. Nausea tops the list, especially during the first few weeks and after each dose increase. Vomiting, diarrhea, constipation, and abdominal discomfort are also common. For most people, these side effects are mild to moderate and fade as the body adjusts. Eating smaller meals, avoiding fatty foods, and staying hydrated can help.
Less common but more serious risks include gallstones, which occurred in about 1.5% of people taking semaglutide injections compared to 0.4% on placebo. Pancreatitis (inflammation of the pancreas) has been reported in rare cases, though study data have shown similar rates between semaglutide and placebo groups.
The FDA requires a boxed warning on semaglutide products about a potential risk of thyroid tumors. In animal studies, the drug caused a specific type of thyroid cancer in rodents. This hasn’t been confirmed in humans, but as a precaution, Ozempic is not prescribed to anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2.
What Happens if You Stop
Weight regain after stopping semaglutide is well documented. The drug suppresses appetite for as long as you take it, but those effects fade once you stop. Studies consistently show that people regain a substantial portion of lost weight within a year of discontinuation. This doesn’t mean the medication “didn’t work.” It means obesity, for many people, is a chronic condition that requires ongoing treatment, similar to how blood pressure medication controls hypertension without curing it.
Some people use semaglutide as a bridge, losing weight on the medication while building exercise and dietary habits that help maintain results. Others stay on it long term. The right approach depends on individual circumstances.
How Semaglutide Compares to Tirzepatide
Tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss) is the main competitor. It works on two gut hormones instead of one, targeting both GLP-1 and GIP receptors. In a head-to-head trial, tirzepatide produced 47% greater weight loss than semaglutide: participants lost an average of 20.2% of their body weight on tirzepatide compared to 13.7% on semaglutide. In practical terms, that was about 50 pounds versus 33 pounds.
Tirzepatide also showed greater reductions in waist circumference: 7.2 inches lost versus 5.1 inches with semaglutide. The side effect profiles are similar, with nausea and other GI symptoms being the primary complaints for both drugs. Cost and insurance coverage vary, and availability has been limited by high demand for both medications.
Who Typically Gets a Prescription
Because Ozempic’s official approval is for type 2 diabetes, the formal prescribing criteria center on blood sugar management. For weight loss specifically, doctors generally follow the same BMI guidelines used for Wegovy: a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, or sleep apnea.
Telehealth platforms and weight loss clinics have made access easier in recent years, though prescribing standards vary. The medication is not appropriate for people who are mildly overweight without other health concerns, and it isn’t a cosmetic tool for losing a few vanity pounds. It carries real risks and costs, and the benefits are most meaningful for people whose excess weight poses a genuine threat to their health.